Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration.
Jelena P SeferovicRhonda Bentley-LewisBrian ClaggettRafael DiazHertzel C GersteinLars V KøberFrancesca C LawsonEldrin F LewisAldo P MaggioniJohn J V McMurrayJeffrey L ProbstfieldMatthew C RiddleScott D SolomonJean-Claude TardifMarc A PfefferPublished in: Journal of diabetes research (2018)
In patients with T2DM and recent ACS, a history of retinopathy and/or neuropathy and longer T2DM duration could be considered clinical markers for high risk of recurrent CV events. This trial is registered with the ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome), ClinicalTrials.gov registration number NCT01147250.